



Healthcare
made
practical

Extended-Release Viloxazine Compared With Atomoxetine For ADHD

Roundtable Discussion

Participants



Greg Mattingly, MD

*Midwest
Research Group*



**Rabbi Richard
Louis Price, MD**

*Weill Cornell Medical
College/New York-
Presbyterian Hospital*



Birgit H Amann, MD

*Behavioral
Medical Center*

Agenda

Time	Topic
8:00 AM – 8:10 AM (10 min)	<i>Welcome and Introductions</i>
8:10 AM – 8:35 AM (25 min)	<i>Theme 1: Current ADHD Treatment Landscape</i>
8:35 AM – 9:20 AM (45 min)	<i>Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study</i>
9:20 AM – 9:30 AM (10 min)	<i>Break</i>
9:30 AM – 9:50 AM (20 min)	<i>Theme 3: Remaining Unmet Needs in ADHD</i>
9:50 AM – 10:00 AM (10 min)	<i>Closing Remarks</i>

Objectives

- Highlight the current ADHD treatment landscape and how it is evolving in light of recent data
- Discuss key findings of the extended-release viloxazine compared with atomoxetine for ADHD study and implications of the study findings
- Identify current unmet needs in ADHD

Theme 1:
Current ADHD Treatment Landscape

Theme 1: Current ADHD Treatment Landscape

Goals

- ✓ *Highlight recent advancements in the ADHD landscape and current treatment approaches for the treatment of adults and pediatric patients*
- ✓ *Recognize the role of nonstimulants for the treatment of ADHD*

Discussion Topics

- 1) Current ADHD treatment options (eg, psychostimulants, nonstimulants)
- 2) Clinical decision-making approaches in both adults and pediatric patients
- 3) The role of nonstimulants such as viloxazine ER in the current treatment paradigm

Theme 1: Current ADHD Treatment Landscape

Goal:

- ✓ *Highlight recent advancements in the ADHD landscape and current treatment approaches for the treatment of adults and pediatric patients*
- ✓ *Recognize the role of nonstimulants for the treatment of ADHD*

Key Questions

- Please describe your current clinical decision-making process in adults and pediatric patients, respectively
- What are the key disease/patient factors that ultimately drive your treatment decisions?
- Considering the rising prevalence of ADHD diagnoses, how, if at all, has this impacted your clinical approach?

Theme 1: Current ADHD Treatment Landscape

Goal:

- ✓ *Highlight recent advancements in the ADHD landscape and current treatment approaches for the treatment of adults and pediatric patients*
- ✓ *Recognize the role of nonstimulants for the treatment of ADHD*

Key Questions (cont'd)

- In what patient types are psychostimulants, alpha-2 agonists, and nonstimulants, respectively, currently being utilized in in your treatment algorithm?
- What is your rationale for reserving psychostimulants predominantly for inattentive ADHD and extended-release alpha-2 agonists for hyperactivity/impulsivity?
- What, if any, clinically meaningful recent advancements in the ADHD treatment landscape that you anticipate will/may impact clinical practice?

**Theme 2:
Viloxazine ER Compared With Atomoxetine
For ADHD Study**

Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

Goal


- ✓ *Discuss key findings of the extended-release viloxazine compared with atomoxetine for ADHD study and implications of the study findings*

Discussion Topics

- 1) Efficacy of viloxazine ER in improving inattention and hyperactivity/impulsivity
- 2) Rapid response time of viloxazine ER compared with atomoxetine
- 3) Tolerability and safety profile of viloxazine ER versus atomoxetine
- 4) Implications on treatment decision-making based on the study


Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

ADHD-Rating Scale-5 (ADHD-RS-5)
at baseline, on atomoxetine, and on viloxazine ER





Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

Adult Investigator Symptom Rating Scale (AISRS)
at baseline, on atomoxetine, and on viloxazine ER



Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

Cumulative percent of children and adults with positive response per week to viloxazine ER compared with atomoxetine



Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

Safety Results

- No patients discontinued treatment prior to 4 weeks due to lack of response
- 36% of patients discontinued atomoxetine due to side effects including GI upset (6), irritability (6), fatigue (5) and insomnia (1)
- 4% of patients discontinued viloxazine ER due to fatigue

Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

Goal

- ✓ *Discuss key findings of the extended-release viloxazine compared with atomoxetine for ADHD study and implications of the study findings*

Key Questions

- What are your overall thoughts on the efficacy results? Safety results?
- What are the most clinically meaningful outcomes of this study, and why?
- What is the clinical significance of the difference in rapidity of response between viloxazine ER and atomoxetine?
- Do the study findings align with what is observed in your clinical practice? Why or why not?

Theme 2: Viloxazine ER Compared With Atomoxetine For ADHD Study

Goal

- ✓ Discuss key findings of the extended-release viloxazine compared with atomoxetine for ADHD study

Key Questions (cont'd)

- How might these findings influence your clinical approach to patients with combined type ADHD?
- Do you consider the data clinically meaningful enough to rationalize the use of viloxazine ER over atomoxetine in your treatment decision-making process? Why or why not?
- How, if at all, do you anticipate the study findings will influence clinical practice in the immediate future?

Break

Theme 3:
Remaining Unmet Needs in ADHD

Theme 3: Remaining Unmet Needs in ADHD

Goal

- ✓ *Identify current unmet needs in the ADHD landscape*

Discussion Topics

- 1) Current unmet needs for the treatment of ADHD in adults and pediatric patients for clinicians
- 2) Current unmet needs for the treatment of ADHD in adults and pediatric patients for patients

Theme 3: Remaining Unmet Needs in ADHD

Goal

- ✓ *Identify current unmet needs in the ADHD landscape*

Key Questions

- Please describe the current challenges faced in your clinical practice when treating adults and pediatric patients with ADHD from a clinician perspective and from a patient perspective, respectively
- What are the main unmet needs in the overall ADHD landscape to be prioritized for clinicians and patients, respectively?

Closing Remarks

Closing Remarks

Goal

- ✓ *Summarize key takeaways from the session discussion and allow for any additional comments regarding the study and the overall ADHD landscape*

Discussion Topics

- 1) Closing remarks on key takeaways from the session discussion
- 2) Additional overall comments regarding the study and the overall ADHD landscape

Closing Remarks

Goal

- ✓ *Summarize key takeaways from the session discussion and allow for any additional comments regarding the study and the overall ADHD landscape*

Key Questions

- Please summarize key takeaways from today's session discussion
- Any additional comments, if at all, regarding the study and the overall ADHD landscape?

Thank You!